News & Events
2026 ATGC Subsidy Program Announced for Technion Researchers
Monday , 6 July 2026
Following three successful years that enabled many of you to conduct cutting-edge genomic experiments in-house, we’re excited to share that RTICC will continue to support ATGC project subsidies through 2026.
Eligible applicants include:
-
Technion researchers with an active MOSAD-funded project
-
Researchers supported by a Rappaport Institute budget
-
New Technion faculty (joined within the last five years) with a procurement budget
-
Physician-researchers affiliated with Technion medical center
As in previous years, subsidies will cover 40% of basic applications and 70% of advanced applications, as detailed in the table below. Please provide your reimbursement budget at 2070. Once processed, the refund will appear under expenses category 600400 – technical assistance refund.
| Basic Application (40% refund) | Advanced Application (70% refund) |
| DNAseq | RNAseq |
| ChIPseq | scRNAseq |
| Cut&Run | scRNAseq+TCR/BCR |
| Amplicon-seq | snATACseq |
| 16S/18S | scMultiomics |
| RRBS | Spatial transcriptomics – VisiumHD |
| miRNAseq | Spatial transcriptomics – CosMx |
| Exome | DNAseq long-reads |
| NGS runs | — |
| NGS runs |
📌 Important: If you have worked with us between January 2025 and today, you're eligible to submit a retroactive request. We encourage you to do so promptly so that reimbursements can be processed right after Passover.
👉 Submit Your Subsidy Request Here
For any questions, feel free to reach out.
— Liat
Psifas Initiative: Advancing Precision Medicine Through Israel's National Genomic Research Infrastructure
Tuesday,21 Oct 2025
Yesterday, Prof. Gabi Barbash, CEO of the Psifas Initiative, gave a lecture at the Faculty of Medicine at the Technion.
During the talk, Prof. Barbash presented Psifas - Israel’s national initiative that has established a cutting-edge infrastructure for medical and genomic research based on clinical and genomic data from approximately 60,000 volunteers across the country.
Through the infrastructure developed within the Psifas Initiative, researchers from healthcare, academia, and industry - in Israel and around the world - can conduct groundbreaking studies that advance the field of precision medicine.
Prof. Barbash discussed the Israeli Reference Genome Study (IRGS), ongoing prospective studies conducted through the Psifas Initiative, and the mapping of actionable genes - clinically significant genetic findings collected within Psifas that can support early detection and prevention of disease.
For more information about the initiative and research proposal submissions, see here -
https://partnership.psifas.org.il/